sangamo in the news
BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 6, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas. The shares outstanding are 141.56M, and float is at 116.56M with Short Float at 13.35%. 287 institutions hold shares in Sangamo Therapeutics Inc. (SGMO), with 25.21M shares held by insiders accounting for 17.60% while institutional investors hold 70.92% of the company’s shares. It is also 63.73% off the consensus price target high of $30.00 offered by 11 analysts, but current levels are 9.33% higher than the price target low of $12.00 for the same period. The stock witnessed a -23.33% loss in the last 1 month and extending the period to 3 months gives it a 10.34%, and is -9.26% down over the last 5 days. Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify's iPSC- and ESC-derived regulatory T cells (SGMO, Press Releases / Tue, 06:00am) Friday, April 17, 2020 Following the sale, the insider now owns 65978.0 shares. Wall Street brokerages expect Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to post $31.88 million in sales for the current fiscal quarter, Zacks reports. Feb. 24, 2021 4:01 PM ET Sangamo Therapeutics, Inc. (SGMO) By: Gaurav Batavia, SA News Editor. The shares outstanding are 141.56M, and float is at 116.56M with Short Float at 13.35%. Join now to get the NewsHeater.com pre-market morning brief 100% free. SGMO has fallen -$0.51 from the previous closing price of $17.94 on volume of 998,638 shares. The trade occurred on Dec 24 and was made at $18.13 per share for $60391.0. Sangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene regulation. //-->
